• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23847 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of the tiered system of emergency structures in hospitals]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for prostate cancer]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [SSRI / SSNRI: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tricyclic antidepressants: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Agility training: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anticonvulsants: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Strength training: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endurance training: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cognitive behavioural therapy: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cognitive behavioural therapy for insomnia: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mindfulness-based stress reduction: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Consumer health information on lung cancer screening using low-dose computed tomography]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Consumer health information on smoking cessation options]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for implantation of unicondylar sled prosthesis - Update of Project V21-02]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome in knee replacement revision surgery - Update of Project V21-03]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for total knee replacement – Update of Project V21-01]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Scientific evaluation of the relationship between volume of services and quality of treatment outcome for rare diseases]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of cardiac magnetic resonance imaging in coronary heart disease]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Radiofrequency energy treatment for organic erectile dysfunction]
2025     Norwegian Medical Products Agency (NOMA) Intravenous ketamine for treatment-resistant depression
2025     Belgian Health Care Knowledge Centre (KCE) Economic evaluation of whole genome sequencing for children with developmental disorders (Study 2024-09)
2025     Belgian Health Care Knowledge Centre (KCE) Update of prostate cancer screening recommendations (Study 2024-10)
2025     Belgian Health Care Knowledge Centre (KCE) Update of breast cancer screening recommendations (Study 2024-11)
2025     Belgian Health Care Knowledge Centre (KCE) Evaluation of novel blood-based brain biomarkers for mild traumatic brain injuries (Study 2023-11)
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Early detection of graft damage in kidney and heart recipient patients using donor-derived free DNA (dd-cfDNA)]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Branched endovascular prostheses for the treatment of aortic arch pathology]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety and clinical effectiveness of cryoanalgesia in pediatric patients after surgical intervention for pectus excavatum]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness of care models based on the incorporation of psychologists in primary care]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Diagnostic accuracy of ex vivo confocal microscopy during Mohs surgery for basal cell carcinomas]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical practice guideline (CPG) update palliative care]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical practice guideline on deprescribing antidepressants]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) Monitoring study protocol: left ventricular assist devices destination therapy
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Adaptive deep brain stimulation in Parkinson's disease]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Lattice radiotherapy in the curative or palliative treatment of deep, large-volume tumors and metastatic or unresectable disease]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Assesment of artificial intelligence´s diagnostic yield and security in cardiac monitoring using insertable cardiac monitors]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [SSRI/SSNRI: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cognitive behavioural therapy: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Gabapentin: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Clonidine: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cimicifuga: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for major liver resection]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Irradiation of the skin with intense pulsed light and radiofrequency for stage I and II hidradenitis suppurativa (Hurley Score)]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vulvodynia (itching and pain in the vulva area): What non-drug treatment options are promising?]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Adhesions in the abdominal cavity: Do other measures help to relieve symptoms instead of surgery?]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Revision of the information materials on colorectal cancer screening]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Development of a decision aid for aortic aneurysm interventions]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Early detection of colorectal cancer in people with a family risk]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP "Rheumatoid Arthritis“]
2025     Swiss Federal Office of Public Health (FOPH) Multigene-expression tests for breast cancer
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Effectiveness and complications of preimplantation genetic testing for aneuploidies (PGT-A) in in vitro fertilisation (IVF)]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Alternative methods to coercive measures]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Intraoperative Radiation Therapy for Breast Cancer]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of phalloplasty as a masculinizing genital surgery: a systematic review]
2025     NIHR Health Technology Assessment programme Protocol for DexEnceph: a randomised controlled trial of dexamethasone therapy in adults with herpes simplex virus encephalitis
2024     Canary Health Service [Cost-effectiveness of neonatal screening for spinal muscular atrophy and severe combined immunodeficiency]
2024     Canary Health Service [Psychological interventions in paediatric population eligible for palliative care and their family]
2024     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [The mental health day hospital: drawing on the literature to define the service offer and enhance practice]
2024     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Mechanisms and interventions to prevent intrusive wandering by residents with neurocognitive disorders in long-term care facilities]
2024     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Considerations related to risk treatment in the context of home care for older adults and courses of action to support care providers]
2024     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Physiotherapy interventions for adult with persistent symptoms following mild traumatic brain injury]
2024     Agency for Care Effectiveness (ACE) KidneyIntelX for patients with diabetic kidney disease
2024     Agency for Care Effectiveness (ACE) Organ Care System (OCS) Heart System for heart transplantation of marginal brain-death donor hearts or circulatory-death donor hearts
2024     Agency for Care Effectiveness (ACE) RelieVRx for the treatment of chronic lower back pain
2024     Agency for Care Effectiveness (ACE) Canvas Dx to aid the diagnosis of autism spectrum disorder
2024     Agency for Care Effectiveness (ACE) CavaClear for patients with difficult inferior vena cava filters (IVCFs) retrieval who have failed a previous retrieval method
2024     Agency for Care Effectiveness (ACE) Nerivio for the acute and preventive treatment of migraine
2024     Agency for Care Effectiveness (ACE) Transcutaneous afferent patterned stimulation for patients with essential tremor or Parkinsons Disease
2024     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Point-of-care ultrasound for the evaluation of pulmonary volume overload in an outpatient setting]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Chronic graft-versus-host disease; assessment according to §35a Social Code Book (SGB) V; search for disease registries]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection - iptacopan (paroxysmal nocturnal haemoglobinuria)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection - epcoritamab (relapsed or refractory follicular lymphoma)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection – Odronextamab (relapsed or refractory follicular lymphoma)]
2024     Canary Health Service [Safety and efficacy of the use of compression garments in the treatment of lipedema]
2024     NIHR Health Services and Delivery Research programme Routine outcomes to investigate differences between ethnic minorities and white British people presenting to emergency services for injury: the stakeholder consultation
2024     Austrian Institute for Health Technology Assessment (AIHTA) Telehealth in diabetes – EU mapping and systematic evaluation of organisational aspects
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Botulinum toxin in dystonia, dyspareunia, and strabismus]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Threshold values in health economic evaluations and decision-making
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Strategies for reducing weight stigmatisation towards people with overweight or obesity in the healthcare system]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Artificial Intelligence in health care with a focus on hospitals: methodological considerations for health technology assessment: a scoping review
2024     Austrian Institute for Health Technology Assessment (AIHTA) Oncological breast cancer care in selected European countries: cross-sectoral cancer care models
2024     Austrian Institute for Health Technology Assessment (AIHTA) Mental health screening of adults in primary care
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Massive parallel sequencing – technologies for high-throughput analysis of genetic-genomic data sets]
2024     Gesundheit Osterreich GmbH (GOeG) [Long-term effectiveness of early interventions for children and adolescents with psychological stress]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with heart failure]
2024     Scottish Health Technologies Group (SHTG) Digital fracture liaison service
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Rigid-platform (TEM/ TEO) or flexible-platform (TAMIS) endoscopic transanal surgery for the treatment of rectal lesions]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (NSCLC, adjuvant) – 2nd Addendum to Project A24-73]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polihexanide (Acanthamoeba keratitis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isavuconazole (mucormycosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isavuconazole (aspergillosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (NSCLC, adjuvant) – Addendum to Project A24-73]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Addendum to Project A24-71]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Capivasertib (breast cancer) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (TNBC, neoadjuvant and adjuvant) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Binimetinib and encorafenib (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (urothelial cancer, first line) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial cancer, first line) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Lorviqua (ALK+ NSCLC)]